IRVINE, Calif. January 12, 2026 – BioDuro, a leading global contract research, development, and manufacturing organization (CRDMO), today announced the completion of the sale of its Irvine-based drug product facility to Forma Life Sciences, Inc., a Delware entity formed by BioSelective Capital Investments and Shayan Enterprises, LLC, for the purpose of the acquisition.
BioDuro emphasized that the transaction does not change the company's identity or strategic footprint in the United States. BioDuro remains a U.S. company, with its global headquarters continuing to be based in Irvine, California.
"This divestiture is a strategic step that allows BioDuro to further sharpen our focus on our core strengths in drug discovery and drug substance development and manufacturing," said Dr. Armin Spura, CEO of BioDuro. "By streamlining our portfolio, we are better positioned to allocate resources and expertise where we deliver the greatest value to our partners."
BioDuro continues to maintain a dedicated drug product team based in China, with a strong focus on supporting IND filings and enabling early clinical success for global customers. This team remains an integral part of BioDuro's integrated development capabilities, particularly for first-in-human and early clinical programs.
The company remains committed to providing high-quality, integrated solutions across drug discovery, process development, and manufacturing, while continuing to support customers worldwide with scientific excellence, operational agility, and a strong regulatory track record.
About BioDuro
BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive IND-enabling capabilities, including both drug substance and drug product development.
About BioSelective Capital Investment
BioSelective Capital Investments, and Shayan Enterprises, LLC, a Utah-based risk-capital investment company, selectively invest in the biopharmaceutical sector through collaborations that tightly merge equity investments with hands-on operational partnerships. With over 10 active projects our investments have a track record for delivering sustainable revenue growth and maximized profit margins with careful attention to sales growth and cost containment, especially for young start-ups and pre-profit companies. We deploy motivated and culturally diverse teams, along with capital, for well-defined and measurable goals to build operational accountability and to energize sales teams to meet critical milestones and revenue targets. We are BioSelective.
Media Enquiries
Christina Coby
Associate Director, BioDuro
Email: christina.coby@bioduro.com
Mobile: +1 (619) 414 7409
Chris Halling
Director, Communications & Content, Orientation Marketing
Email: Chris.Halling@orientation.agency
Mobile: +44 (0)7580 041073
Home
